Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
August 22, 2007
By: Tim Wright
Frank A. D’Amelio has been named senior vice president and chief financial officer of Pfizer, effective in mid-September. Mr. D’Amelio is a senior executive with almost three decades of operating and financial experience at AT&T, Lucent Technologies and Alcatel-Lucent, including serving as chief operating officer and chief financial officer at Lucent. Mr. D’Amelio is currently senior executive vice president, integration and chief administrative officer at Alcatel-Lucent. He will join Pfizer’s executive leadership team and report to Jeff Kindler, Pfizer’s chairman and chief executive officer. He will have responsibility for all aspects of the company’s finances, including treasury, tax, the controller’s division and investor development. He succeeds Alan Levin, who announced plans to retire from Pfizer in May. “We are very pleased that an executive with Frank’s skills, integrity, global experience and proven leadership is joining our management team,” said Mr. Kindler. “Through almost three decades . . . Frank was a senior executive in global companies undergoing the kind of rapid and complex changes we have undertaken at Pfizer in response to our own rapidly changing markets. Mr. D’Amelio began his career in 1979 at AT&T Bell Labs, where he held various financial, accounting and general management positions. He also served as vice president and chief financial officer of Lucent’s Network Systems Business and in 1996, he helped establish the financial structure of the new Lucent company. Prior to being named executive vice president, administration and chief financial officer of Lucent in May 2001, Mr. D’Amelio was group president of Lucent’s Switching Solutions Group, where he led the manufacturing, R&D, marketing and product management of Lucent’s switching, access and applications software businesses. In early 2006 Mr. D’Amelio was appointed Lucent’s chief operating officer, responsible for leading the operations of the business including sales, the product groups, the services business, the supply chain, IT operations and labor relations. After Lucent merged with Alcatel later in 2006, Mr. D’Amelio was appointed senior executive vice president, integration and chief administrative officer.
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !